» Articles » PMID: 12475915

Suppression of Fas-FasL-induced Endothelial Cell Apoptosis Prevents Diabetic Blood-retinal Barrier Breakdown in a Model of Streptozotocin-induced Diabetes

Overview
Journal FASEB J
Specialties Biology
Physiology
Date 2002 Dec 12
PMID 12475915
Citations 88
Authors
Affiliations
Soon will be listed here.
Abstract

Diabetic macular edema, resulting from increased microvascular permeability, is the most prevalent cause of vision loss in diabetes. The mechanisms underlying this complication remain poorly understood. In the current study, diabetic vascular permeability (blood-retinal barrier breakdown) is demonstrated to result from a leukocyte-mediated Fas-FasL-dependent apoptosis of the retinal vasculature. Following the onset of streptozotocin-induced diabetes, FasL expression was increased in rat neutrophils (P<0.005) and was accompanied by a simultaneous increase in Fas expression in the retinal vasculature. Static adhesion assays demonstrated that neutrophils from diabetic, but not control, rats induced endothelial cell apoptosis in vitro (P<0.005). The latter was inhibited via an antibody-based FasL blockade (P<0.005). In vivo, the inhibition of FasL potently reduced retinal vascular endothelial cell injury, apoptosis, and blood-retinal barrier breakdown (P<0.0001) but did not diminish leukocyte adhesion to the diabetic retinal vasculature. Taken together, these data are the first to identify leukocyte-mediated Fas-FasL-dependent retinal endothelial cell apoptosis as a major cause of blood-retinal barrier breakdown in early diabetes. These data imply that the targeting of the Fas-FasL pathway may prove beneficial in the treatment of diabetic retinopathy.

Citing Articles

In situ visualization of endothelial cell-derived extracellular vesicle formation in steady state and malignant conditions.

Atkin-Smith G, Santavanond J, Light A, Rimes J, Samson A, Er J Nat Commun. 2024; 15(1):8802.

PMID: 39438460 PMC: 11496675. DOI: 10.1038/s41467-024-52867-5.


Senescent endothelial cells: a potential target for diabetic retinopathy.

Liao Y, Fang Y, Sun J, Dou G Angiogenesis. 2024; 27(4):663-679.

PMID: 39215875 PMC: 11564237. DOI: 10.1007/s10456-024-09943-7.


Tocotrienol-rich fraction (TRF) protects against retinal cell apoptosis and preserves visual behavior in rats with streptozotocin-induced diabetic retinopathy.

Goh Y, Sadikan M, Jaiprakash H, Abdul Nasir N, Agarwal R, Iezhitsa I BMC Complement Med Ther. 2024; 24(1):322.

PMID: 39215295 PMC: 11365272. DOI: 10.1186/s12906-024-04614-y.


Elucidating the role of genetically determined metabolites in Diabetic Retinopathy: insights from a mendelian randomization analysis.

Tan Y, Yan Z, Yin J, Cao J, Xie B, Zhang F Acta Diabetol. 2024; 62(2):193-203.

PMID: 39090426 DOI: 10.1007/s00592-024-02345-7.


Cell and molecular targeted therapies for diabetic retinopathy.

Reddy S, Devi V, Seetharaman A, Shailaja S, Bhat K, Gangaraju R Front Endocrinol (Lausanne). 2024; 15:1416668.

PMID: 38948520 PMC: 11211264. DOI: 10.3389/fendo.2024.1416668.